MCQ Quiz: Injectable Diabetes Drugs

Injectable medications are the cornerstone of therapy for Type 1 diabetes and a critical component of management for many patients with Type 2 diabetes. This therapeutic category has expanded beyond traditional insulins to include sophisticated agents like GLP-1 receptor agonists, a topic covered in detail in the “Pharmacology of Injectable Diabetes Medications” lecture within the Patient Care 5 curriculum. Mastering the use, counseling, and nuances of these drugs is an essential skill for every pharmacist. This quiz will test your knowledge on the clinical application of insulin analogs, GLP-1 agonists, and other injectable diabetes therapies.

1. Which of the following is a long-acting (basal) insulin?

  • a. Insulin lispro
  • b. Insulin aspart
  • c. Insulin glargine
  • d. Regular insulin

Answer: c. Insulin glargine

2. A patient is prescribed insulin aspart. When should they be counseled to inject this medication?

  • a. 30-60 minutes before a meal.
  • b. Once daily at bedtime.
  • c. Within 15 minutes before or immediately after starting a meal.
  • d. In the morning, regardless of meals.

Answer: c. Within 15 minutes before or immediately after starting a meal.

3. GLP-1 receptor agonists, such as liraglutide, work by which primary mechanism?

  • a. They stimulate insulin release in a glucose-dependent manner and slow gastric emptying.
  • b. They block glucose reabsorption in the kidneys.
  • c. They increase insulin sensitivity in peripheral tissues.
  • d. They inhibit the breakdown of carbohydrates in the gut.

Answer: a. They stimulate insulin release in a glucose-dependent manner and slow gastric emptying.

4. A common side effect when initiating a GLP-1 receptor agonist is:

  • a. Hypoglycemia
  • b. Weight gain
  • c. Nausea
  • d. Constipation

Answer: c. Nausea

5. What is the most critical counseling point for a patient starting any type of insulin?

  • a. The color of the insulin pen.
  • b. The signs, symptoms, and treatment of hypoglycemia.
  • c. The cost of the medication.
  • d. The mechanism of action of the insulin.

Answer: b. The signs, symptoms, and treatment of hypoglycemia.

6. The “Pharmacology of Injectable Diabetes Medications” is a specific lecture in which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5104 Sterile Compounding
  • c. PHA5703 Pharmacy Law and Ethics
  • d. PHA5878C Patient Care 3

Answer: a. PHA5787C Patient Care 5

7. A “basal-bolus” insulin regimen is designed to mimic the body’s natural insulin secretion and consists of:

  • a. A long-acting insulin once daily plus a rapid-acting insulin with meals.
  • b. NPH insulin twice daily.
  • c. Only a rapid-acting insulin.
  • d. A premixed insulin twice daily.

Answer: a. A long-acting insulin once daily plus a rapid-acting insulin with meals.

8. Which of the following insulins is available as a U-500 concentration and is reserved for patients with severe insulin resistance?

  • a. Insulin glargine
  • b. Insulin lispro
  • c. Regular insulin
  • d. Insulin aspart

Answer: c. Regular insulin

9. Pramlintide is an injectable medication that is a synthetic analog of which hormone?

  • a. Glucagon
  • b. Amylin
  • c. Somatostatin
  • d. Gastrin

Answer: b. Amylin

10. A major counseling point for a patient starting pramlintide is that:

  • a. It should be mixed in the same syringe with insulin.
  • b. The mealtime insulin dose must be reduced by about 50% to prevent severe hypoglycemia.
  • c. It causes significant weight gain.
  • d. It should be taken on an empty stomach without eating.

Answer: b. The mealtime insulin dose must be reduced by about 50% to prevent severe hypoglycemia.

11. The management of diabetes is a topic within the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

12. Which of the following GLP-1 receptor agonists is administered once weekly?

  • a. Liraglutide
  • b. Exenatide (Byetta)
  • c. Dulaglutide
  • d. Lixisenatide

Answer: c. Dulaglutide

13. A patient is counseled to rotate their insulin injection sites to prevent:

  • a. A decrease in the insulin’s potency.
  • b. Lipohypertrophy, which can impair insulin absorption.
  • c. An allergic reaction.
  • d. The injection from being too painful.

Answer: b. Lipohypertrophy, which can impair insulin absorption.

14. Which type of insulin is cloudy in appearance?

  • a. Insulin glargine
  • b. Insulin aspart
  • c. NPH insulin
  • d. Insulin detemir

Answer: c. NPH insulin

15. Educating a patient on how to monitor their blood glucose is a key objective for student pharmacists.

  • a. True
  • b. False

Answer: a. True

16. GLP-1 receptor agonists have a black box warning for a risk of what, based on rodent studies?

  • a. Pancreatitis
  • b. Myocardial infarction
  • c. Thyroid C-cell tumors
  • d. Severe hypoglycemia

Answer: c. Thyroid C-cell tumors

17. The management of diabetes complications is a topic within the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

18. Which insulin can be administered via an intravenous (IV) infusion?

  • a. Insulin glargine
  • b. NPH insulin
  • c. Regular insulin
  • d. Insulin degludec

Answer: c. Regular insulin

19. A patient experiences hypoglycemia. According to the “Rule of 15,” what should they do?

  • a. Consume 15 grams of protein and recheck in 15 minutes.
  • b. Consume 15 grams of a simple carbohydrate and recheck in 15 minutes.
  • c. Inject 15 units of insulin.
  • d. Call their doctor and wait 15 minutes.

Answer: b. Consume 15 grams of a simple carbohydrate and recheck in 15 minutes.

20. An active learning session on diabetes is part of the Patient Care 5 course.

  • a. True
  • b. False

Answer: a. True

21. A key benefit of GLP-1 receptor agonists and SGLT2 inhibitors compared to insulin or sulfonylureas is:

  • a. A significantly lower risk of hypoglycemia when used as monotherapy.
  • b. They are all available as oral tablets.
  • c. They are much less expensive.
  • d. They have no side effects.

Answer: a. A significantly lower risk of hypoglycemia when used as monotherapy.

22. A patient’s unopened insulin vials and pens should be stored in:

  • a. The freezer.
  • b. A cabinet at room temperature.
  • c. The refrigerator.
  • d. A warm place to prevent crystallization.

Answer: c. The refrigerator.

23. Displaying appropriate techniques when counseling patients on new medications is a key objective.

  • a. True
  • b. False

Answer: a. True

24. Which of the following is a potential side effect of pramlintide?

  • a. Severe nausea
  • b. Hypertension
  • c. Weight gain
  • d. Hyperglycemia

Answer: a. Severe nausea

25. A pharmacist’s role in managing injectable diabetes therapy includes:

  • a. Educating on proper injection and disposal techniques.
  • b. Counseling on hypoglycemia management.
  • c. Recommending appropriate insulin regimen adjustments.
  • d. All of the above.

Answer: d. All of the above.

26. The “lag time” of regular insulin means it needs to be injected how long before a meal?

  • a. 5 minutes
  • b. 15 minutes
  • c. 30-60 minutes
  • d. It can be injected after the meal.

Answer: c. 30-60 minutes

27. A patient with Type 1 diabetes needs which type of insulin for survival?

  • a. Only a rapid-acting (bolus) insulin.
  • b. Only a long-acting (basal) insulin.
  • c. Both a basal and a bolus insulin.
  • d. No insulin is needed if they follow a strict diet.

Answer: c. Both a basal and a bolus insulin.

28. An active learning session on diabetes is part of which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5787C Patient Care 5

29. The main reason for the development of rapid-acting insulin analogs was to:

  • a. Create a cheaper insulin.
  • b. Better mimic the natural, rapid insulin release in response to a meal and improve convenience.
  • c. Provide a once-daily insulin.
  • d. Reduce the risk of injection site reactions.

Answer: b. Better mimic the natural, rapid insulin release in response to a meal and improve convenience.

30. The medicinal chemistry of diabetes medications is a topic within the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

31. What is the primary advantage of ultra-long-acting insulins like degludec?

  • a. They have a peak effect that covers mealtime glucose excursions.
  • b. They have a very long, flat, and consistent duration of action, leading to lower rates of nocturnal hypoglycemia.
  • c. They can be mixed with any other insulin.
  • d. They are administered intravenously.

Answer: b. They have a very long, flat, and consistent duration of action, leading to lower rates of nocturnal hypoglycemia.

32. A common counseling point for a patient using an insulin pen is:

  • a. To share the pen with a family member.
  • b. To reuse needles multiple times.
  • c. To perform a “prime” shot (air shot) before each injection to ensure the needle is patent.
  • d. To store the pen in the freezer after opening.

Answer: c. To perform a “prime” shot (air shot) before each injection to ensure the needle is patent.

33. Besides glycemic control, which class of injectable diabetes medications has demonstrated significant cardiovascular benefits?

  • a. NPH insulin
  • b. GLP-1 receptor agonists
  • c. Regular insulin
  • d. Pramlintide

Answer: b. GLP-1 receptor agonists

34. A patient should be counseled to inject their subcutaneous insulin into which tissue?

  • a. Muscle
  • b. A vein
  • c. Adipose (fatty) tissue
  • d. A bone

Answer: c. Adipose (fatty) tissue

35. A patient’s insulin-to-carb ratio (ICR) is 1:10. If they are about to eat a meal containing 60 grams of carbohydrates, how many units of rapid-acting insulin do they need for the meal?

  • a. 4 units
  • b. 6 units
  • c. 10 units
  • d. 15 units

Answer: b. 6 units

36. A patient reports that their NPH insulin is clear. The pharmacist should advise them that:

  • a. This is normal.
  • b. The insulin is likely expired or denatured and should not be used.
  • c. They should shake it vigorously until it becomes cloudy.
  • d. They should warm it up.

Answer: b. The insulin is likely expired or denatured and should not be used.

37. Which of the following is NOT a common injection site for insulin?

  • a. Abdomen
  • b. Back of the upper arm
  • c. Thigh
  • d. Forearm

Answer: d. Forearm

38. The management of diabetes is an active learning session in the Patient Care 5 course.

  • a. True
  • b. False

Answer: a. True

39. A patient’s opened vial of insulin lispro should be stored:

  • a. In the refrigerator for up to one year.
  • b. At room temperature and discarded after 28 days.
  • c. In the freezer.
  • d. In direct sunlight.

Answer: b. At room temperature and discarded after 28 days.

40. An active learning session covering diabetes is part of which course module?

  • a. Module 1: Diabetes Mellitus
  • b. Module 3: Women’s Health
  • c. Module 4: Medication Safety
  • d. Module 8: Men’s Health

Answer: a. Module 1: Diabetes Mellitus

41. The primary therapeutic effect of amylin (and its analog pramlintide) is on:

  • a. Basal glucose control.
  • b. Post-prandial (after-meal) glucose control.
  • c. Overnight glucose control.
  • d. Fasting glucose control.

Answer: b. Post-prandial (after-meal) glucose control.

42. Which of the following is an example of a premixed insulin?

  • a. Humalog (insulin lispro)
  • b. Lantus (insulin glargine)
  • c. Novolog Mix 70/30 (70% insulin aspart protamine, 30% insulin aspart)
  • d. Levemir (insulin detemir)

Answer: c. Novolog Mix 70/30 (70% insulin aspart protamine, 30% insulin aspart)

43. A patient with a severe needle phobia may be a candidate for which type of insulin delivery?

  • a. An inhaled insulin
  • b. An oral insulin
  • c. An insulin pump
  • d. A topical insulin

Answer: c. An insulin pump

44. What is a key counseling point when starting a once-weekly GLP-1 RA like Ozempic or Trulicity?

  • a. The injection should be given on the same day each week.
  • b. The dose must be taken with food.
  • c. It can be mixed with insulin.
  • d. It causes severe hypoglycemia.

Answer: a. The injection should be given on the same day each week.

45. Which insulin does not have a pronounced peak?

  • a. Regular
  • b. NPH
  • c. Aspart
  • d. Glargine

Answer: d. Glargine

46. A pharmacist’s role in injectable diabetes therapy is critical for:

  • a. Patient education and device training.
  • b. Improving adherence.
  • c. Preventing medication errors (e.g., confusing different insulins).
  • d. All of the above.

Answer: d. All of the above.

47. A patient taking pramlintide should be counseled to inject it:

  • a. At the same time as their insulin, but at a different injection site.
  • b. Only at bedtime.
  • c. Only in the morning.
  • d. Once a week.

Answer: a. At the same time as their insulin, but at a different injection site.

48. An active learning session on diabetes is part of which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5787C Patient Care 5

49. The “sliding scale” insulin regimen is now less favored for routine management because:

  • a. It is a proactive approach to glucose management.
  • b. It is a reactive approach that only treats hyperglycemia after it has occurred.
  • c. It has a low risk of hypoglycemia.
  • d. It is too easy for patients to follow.

Answer: b. It is a reactive approach that only treats hyperglycemia after it has occurred.

50. The ultimate goal of using injectable diabetes medications is to:

  • a. Use the most number of injections possible.
  • b. Achieve glycemic targets to prevent the long-term microvascular and macrovascular complications of diabetes.
  • c. Eliminate the need for blood glucose monitoring.
  • d. Provide a cure for diabetes.

Answer: b. Achieve glycemic targets to prevent the long-term microvascular and macrovascular complications of diabetes.

Leave a Comment